Stock AnalizHUTCHMED (China) Ltd HCM
Biotechnology: Pharmaceutical Preparations · IPO 2016 · data as of November 13, 2026
HUTCHMED (China) Ltd (HCM) is a healthcare company listed in the US with a market value of about $2.6B. In the twelve months to June 30, 2026 it had revenue of $549M and net income of $18M, a net margin of 3.3%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).
Key numbers: a P/E of 149.0, a price to free cash flow of 261.3, 5-year revenue growth of 19% a year, a 5-year average ROIC of -19%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 94% below the current price.
Score: 1.4 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
- More cash than debt, or low debt to equity
- Positive free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $549M | $549M | $630M | $838M | $426M | $356M | $228M | $205M | $214M | $241M | $216M |
| Net income | $18M | $457M | $38M | $101M | -$361M | -$195M | -$126M | -$106M | -$75M | -$27M | $12M |
| Free cash flow | $10M | -$79M | -$17M | $187M | -$305M | -$221M | -$70M | -$89M | -$39M | -$14M | -$14M |
| EPS (diluted) | $0.10 | $2.62 | $0.22 | $0.58 | $-2.07 | $-1.12 | $-0.72 | $-0.61 | $-0.43 | $-0.15 | $0.07 |
| Net margin | 3.3% | 83.3% | 6.0% | 12.0% | -84.6% | -54.7% | -55.1% | -51.7% | -34.9% | -11.1% | 5.4% |
| ROIC | — | -2.6% | -4.1% | 2.1% | -63.9% | -25.3% | -29.9% | -36.0% | -17.3% | -8.6% | -15.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $21.14, 42% above the current price; targets range from $13.60 to $33.27; the consensus rating is “Strong buy”; expected EPS is $0.22 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is HUTCHMED (China)’s P/E ratio?
About 149.0, based on the last twelve months of diluted earnings per share (forward P/E about 58.5).
Is HUTCHMED (China) stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 94% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does HUTCHMED (China) pay a dividend?
Not currently.
Is HUTCHMED (China) a good stock to buy?
We do not give buy or sell advice. HUTCHMED (China) scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.